Anti-TPA Tissue Plasminogen Activator 抗体 (ab47033)

製品の概要

  • 製品名Anti-TPA Tissue Plasminogen Activator antibody
    TPA Tissue Plasminogen Activator 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to TPA Tissue Plasminogen Activator
  • アプリケーション適用あり: WB, ICC/IFmore details
  • 種交差性
    交差種: Human
    交差が予測される動物種: Mouse, Rat, Rabbit, Chicken, Cow, Pig
  • 免疫原

    Synthetic peptide conjugated to KLH derived from within residues 250 - 350 of Human TPA Tissue Plasminogen Activator.

    (Peptide available as ab47113.)

  • ポジティブ・コントロール
    • WB: DU 145 and Caco 2 whole cell lysates and TPA recombinant protein. ICC/IF: A431 cells.

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab47033 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
WB Use a concentration of 1 µg/ml. Detects a band of approximately 75 kDa (predicted molecular weight: 63 kDa).
ICC/IF Use a concentration of 10 µg/ml.

ターゲット情報

  • 機能Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration.
  • 組織特異性Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk.
  • 関連疾患Note=Increased activity of TPA results in increased fibrinolysis of fibrin blood clots that is associated with excessive bleeding. Defective release of TPA results in hypofibrinolysis that can lead to thrombosis or embolism.
  • 配列類似性Belongs to the peptidase S1 family.
    Contains 1 EGF-like domain.
    Contains 1 fibronectin type-I domain.
    Contains 2 kringle domains.
    Contains 1 peptidase S1 domain.
  • ドメインBoth FN1 and one of the kringle domains are required for binding to fibrin.
    Both FN1 and EGF-like domains are important for binding to LRP1.
    The FN1 domain mediates binding to annexin A2.
    The second kringle domain is implicated in binding to cytokeratin-8 and to the endothelial cell surface binding site.
  • 翻訳後修飾The single chain, almost fully active enzyme, can be further processed into a two-chain fully active form by a cleavage after Arg-310 catalyzed by plasmin, tissue kallikrein or factor Xa.
    Differential cell-specific N-linked glycosylation gives rise to two glycoforms, type I (glycosylated at Asn-219) and type II (not glycosylated at Asn-219). The single chain type I glycoform is less readily converted into the two-chain form by plasmin, and the two-chain type I glycoform has a lower activity than the two-chain type II glycoform in the presence of fibrin.
    N-glycosylation of Asn-152; the bound oligomannosidic glycan is involved in the interaction with the mannose receptor.
    Characterization of O-linked glycan was studied in Bowes melanoma cell line.
  • 細胞内局在Secreted > extracellular space.
  • Information by UniProt
  • 参照データベース
  • 別名
    • Alteplase antibody
    • DKFZp686I03148 antibody
    • Plasminogen activator tissue antibody
    • Plasminogen activator tissue type antibody
    • PLAT antibody
    • Reteplase antibody
    • t PA antibody
    • T Plasminogen Activator antibody
    • t-PA antibody
    • T-plasminogen activator antibody
    • Tissue plasminogen activator (t PA) antibody
    • Tissue type plasminogen activator antibody
    • Tissue-type plasminogen activator chain B antibody
    • tPA antibody
    • TPA_HUMAN antibody
    • TPA1 antibody
    see all

Anti-TPA Tissue Plasminogen Activator antibody 画像

  • ICC/IF image of ab47033 stained A431 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab47033, 10µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899, DyLight® 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

  • All lanes : Anti-TPA Tissue Plasminogen Activator antibody (ab47033) at 1 µg/ml

    Lane 1 : DU 145 (Human prostate carcinoma cell line) Whole Cell Lysate
    Lane 2 : Caco 2 whole cell lysate (ab3950)

    Lysates/proteins at 10 µg per lane.

    Secondary
    Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution

    Performed under reducing conditions.

    Predicted band size : 63 kDa
    Observed band size : 75 kDa (why is the actual band size different from the predicted?)
    Additional bands at : 55 kDa. We are unsure as to the identity of these extra bands.
    It is probable that this protein runs higher than the predicted MW as it is likely to be glycosylated.
  • Anti-TPA Tissue Plasminogen Activator antibody (ab47033) at 1 µg/ml + TPA recombinant protein at 0.1 µg

    Secondary
    Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution

    Performed under reducing conditions.

    Predicted band size : 63 kDa
    Observed band size : 63 kDa

Anti-TPA Tissue Plasminogen Activator antibody (ab47033) 使用論文

ab47033 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab47033.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"